# CRUINT

> CRUINT is a VC fund in Göd backing Health Care and Neuroscience. See 1 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Göd, Hungary
- Total investments: 1
- Last investment: Aug 2024
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.cruint.com/

CRUINT is a VC fund in Göd focused on Health Care and Neuroscience. CRU network has been providing clinical research services to the pharmaceutical industry for over a decade and basic/academic research services since 2015. In the recent years next to the research activities many new healthcare services were initiated within the EU and in South-East Asia. CRU sites are located in Hungary, Ukraine, Germany,Vietnam and LAO PDR.

## Contacts

5 contacts available for CRUINT. Shizune tracks 1 team members at CRUINT. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/cru-hungary?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 1 | 100% |
| Neuroscience | 1 | 100% |
| Therapeutics | 1 | 100% |
| Pharmaceutical | 1 | 100% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Peter Kovacs | CEO and Managing Director&Owner | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Neuro Therapia | NeuroTherpia, Inc., founded in 2015 by Drs. Mohamed Naguib and Joseph Foss, is developing new therapies for diseases with an underlying component of neuroinflammation. Initial research has led to the development of our lead compound NTRX-07. NTRX-07 (previously known as MDA7) has been shown to decrease activation of microglial cells in the brain.Decreasing activation of these cells leads to decreased inflammation and decreased injury to surrounding nerve cells. Decreasing this inflammation can treat and even prevent the development of neuropathic pain in settings of nerve injury or chemotherapy. Recent work has shown that blocking this inflammation is also important in reversing the effects seen in Alzheimer's disease. We are currently doing preclinical safety studies and plan on studying NTRX-07 in humans in 2016. | $12.3M | Series B | Aug 06, 2024 |  |

1 of 1 investments shown.

## Co-investors
- [Cleveland Clinic](https://shizune.co/investors/profile/cleveland-clinic) — VC Fund, 2 deals together
- [Alzheimer's Drug Discovery Foundation](https://shizune.co/investors/profile/alzheimers-drug-discovery-foundation) — VC Fund, 1 deal together
- [Brain Trust Accelerator Fund](https://shizune.co/investors/profile/brain-trust-accelerator-fund) — VC Fund, 1 deal together
- [Dolby Family Ventures](https://shizune.co/investors/profile/dolby-family-ventures) — VC Fund, 1 deal together
- [Foundation for a Better World](https://shizune.co/investors/profile/foundation-for-a-better-world) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does CRUINT invest in?

CRUINT invests primarily in Health Care, Neuroscience and Therapeutics startups, most often at Series B stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact CRUINT?

Public channels for CRUINT include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at CRUINT?

The team at CRUINT includes Peter Kovacs (CEO and Managing Director&Owner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co